Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment

Next Previous
Trial Profile

Single-Arm, Multicenter, Prospective, Phase 2 Study for the Evaluation of Biomarkers in Patients With Advanced &/or Metastatic Colorectal Cancer With Wild Type KRAS Treated Biweekly With Chemotherapy and Cetuximab as First-Line Treatment

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 18 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms POSIBA

Most Recent Events

  • 13 Sep 2022 Results of small RNA sequencing analysis performed in matched cell-free and exosomal specimens from 29 mCRC patients who received anti-EGFR therapy in PULSE and POSIBA clinical trials presented at the 47th European Society for Medical Oncology Congress
  • 15 Nov 2018 According to a Biocartis media release, results of an analysis of two prospective clinical trials (PULSE; NCT01288339 and POSIBA; NCT01276379) associated with Idylla liquid biopsy were presented at the European Society for Medical Oncology (ESMO) congress (19-23 Oct 2018 in Munich, Germany).
  • 19 Oct 2018 According to a Biocartis media release, results of an analysis of two prospective clinical trials (PULSE; NCT01288339 and POSIBA; NCT01276379) associated with Idylla liquid biopsy will be presented at the European Society for Medical Oncology (ESMO) congress (19-23 Oct 2018 in Munich, Germany).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top